Faculty Profiles - SONE, Hirohito

Papers - SONE, Hirohito

Division display 81 - 100 of about 618 ／ All the affair displays >>

1357-P: Conflicting Significance of High BMI as a Predictor of Individual Diabetic Complications

YUTA YAGUCHI, KAZUYA FUJIHARA, LAY MON KHIN, SIJIA WU, EFREM D. FERREIRA, TAKAAKI SATO, CHIKA HORIKAWA, YASUHIRO MATSUBAYASHI, KIMINORI KATO, HIROHITO SONE

Diabetes 72 ( Supplement_1 ) 2023.6

Publishing type：Research paper (scientific journal) Publisher：American Diabetes Association

Although weight management plays a central role in diabetes treatment, the association between body weight and diabetic complications is not fully elucidated. Therefore, we investigated the relationship between BMI and risk of diabetic complications in patients with diabetes mellius (DM) using nationwide claims data. Analyzed were 91097 patients with DM without prior treatment-requiring diabetic eye disease (TRDED), initiation of dialysis (dialysis), coronary artery disease (CAD), cerebrovascular disease (CVD), heart failure (HF) or amputation (mean age 52 y, HbA1c 7.2%, median follow-up 4.5 y). Participants were divided into 6 groups according to BMI (BMI&lt;20.0, 20.0-22.4, 22.5-24.9, 25.0-27.4, 27.5-29.0, ≥30.0). Risk of diabetic complications was examined by Cox regression analysis. There was an inverse correlation between the risk of dialysis and BMI; hazard ratio (HR) for dialysis in patients with BMI ≥30.0 was 0.46 (0.29-0.74). There was a U-shaped relationship between the risk of HF and BMI; HRs for HF in patients with BMI &lt;20.0 and ≥30.0 were 1.97 (1.15-3.37) and 1.76 (1.27-2.45), respectively (Figure). High BMI was significantly associated with a higher risk of HF, but lower risks of TRDED and dialysis. The relationship between BMI and diabetic complications was inconsistent among complications, suggesting that the target weight should be individualized according to diabetic complications.

<p></p> Disclosure

Y.Yaguchi: None. H.Sone: Research Support; Novo Nordisk, Astellas Pharma Inc., Kyowa Kirin Co., Ltd., Taisho Pharmaceutical Holdings Co., Ltd., Ono Pharmaceutical Co., Ltd., Eisai Co., Ltd., Takeda Pharmaceutical Co., Ltd. K.Fujihara: None. L.Khin: None. S.Wu: None. E.D.Ferreira: None. T.Sato: None. C.Horikawa: None. Y.Matsubayashi: None. K.Kato: None.

DOI： 10.2337/db23-1357-p

researchmap

1381-P: Effect of Dietary Potassium Intake and Its Interaction with Sodium Intake on Risk of Developing Cardiovascular Disease (CVD) in Persons with Type 2 Diabetes (T2D)—Japan Diabetes Complication and Its Prevention Prospective Study (JDCP Study)

CHIKA HORIKAWA, MITSUYOSHI TAKAHARA, NAOTO KATAKAMI, YASUNAGA TAKEDA, MIZUKI TAKEUCHI, KAZUYA FUJIHARA, HIROAKI SUZUKI, KINSUKE TSUDA, NARIHITO YOSHIOKA, HITOSHI SHIMANO, JO SATOH, YASUAKI HAYASHINO, NAOKO TAJIMA, RIMEI NISHIMURA, YOSHIMITSU YAMASAKI, HIROHITO SONE

Diabetes 72 ( Supplement_1 ) 2023.6

Publishing type：Research paper (scientific journal) Publisher：American Diabetes Association

Many guidelines recommend increased potassium intake. However, the relationship between dietary potassium intake and incidence of CVD in persons with T2D has not been explored, nor is it known if this relationship varies with sodium intake in such persons. Therefore, we investigated these relationships as part of the JDCP study, a nationwide study launched in 2007. A total of 1477 persons with T2D aged 40-75 years completed a brief self-administered Diet History Questionnaire at baseline, and resultant data were analyzed. Primary outcome was the 7-year risk of a CVD event. Hazard ratios (HRs) for CVD according to tertiles of dietary potassium and sodium intake were estimated by Cox regression adjusted for confounders in addition to a stratified analysis of tertiles of sodium intake. Mean daily potassium and sodium intakes in tertiles 1 to 3 were 1.9, 2.6, and 3.5 g and 3.3, 4.2, and 5.3 g, respectively. HbA1c, BMI, triglycerides, and blood pressure were well controlled. No significant associations between potassium and sodium intakes and incidence of CVD were shown for the second and third tertiles relative to the first tertile (potassium: 0.64 [95% CI, 0.34-1.23] and 0.59 [0.28-1.25]; sodium: 1.02 [0.51-2.04] and 1.15 [0.58-2.30]). In the stratified analysis of tertiles of sodium intake, in the high sodium intake groups (T2 and T3) HRs for CVD in the high potassium intake group were significantly lower compared to the low potassium intake group (T2: 0.40 [0.12-1.35] and 0.06 [0.01-0.69]; T3: 0.23 [0.07-0.82] and 0.26 [0.07-0.88]). Associations of potassium intake with CVD in those with low sodium intake (T1) were not significant. Findings suggested that high potassium intake under high sodium intake is associated with a deceased incidence of CVD in persons with T2D although potassium intake under low sodium intake was not associated with incident CVD.

Disclosure

C.Horikawa: None. H.Shimano: None. J.Satoh: None. Y.Hayashino: Advisory Panel; Novo Nordisk A/S, Ono Pharmaceutical Co., Ltd., Speaker's Bureau; Boehringer Ingelheim Japan, Inc., Sumitomo Dainippon Pharma Co., Ltd., Santen, Daiichi Sankyo, Kowa Company, Ltd. N.Tajima: None. R.Nishimura: Speaker's Bureau; Sanofi K.K., Medicure Inc., Boehringer Ingelheim Inc., Takeda Pharmaceutical Company Limited, Kissei Pharmaceutical Co., Ltd., Novartis Pharma K.K., Eli Lilly Japan K.K., Novo Nordisk, Merck & Co., Inc., Abbott Japan Co., Ltd., Astellas Pharma Inc., Teijin Pharma Limited, Taisho Pharmaceutical Holdings Co., Ltd., Ono Pharmaceutical Co., Ltd., AstraZeneca. Y.Yamasaki: None. H.Sone: Research Support; Novo Nordisk, Astellas Pharma Inc., Kyowa Kirin Co., Ltd., Taisho Pharmaceutical Holdings Co., Ltd., Ono Pharmaceutical Co., Ltd., Eisai Co., Ltd., Takeda Pharmaceutical Co., Ltd. Jdcp study group: n/a. M.Takahara: None. N.Katakami: Speaker's Bureau; Abbott Japan Co., Ltd., Daiichi Sankyo, MSD, Mitsubishi Tanabe Pharma Corporation, Kowa Company, Ltd., Ono Pharmaceutical Co., Ltd., Novo Nordisk, Sumitomo Dainippon Pharma Co., Ltd., Bayer Inc., Lilly, Teijin Pharma Limited, Kyowa Kirin Co., Ltd., Boehringer Ingelheim Japan, Inc., Sanofi. Y.Takeda: None. M.Takeuchi: None. K.Fujihara: None. H.Suzuki: None. K.Tsuda: None. N.Yoshioka: None.

DOI： 10.2337/db23-1381-p

researchmap

1713-P: Dietary Manganese (Mn) Intake Is Independently Associated with a Lower BMI in Younger Japanese with Type 2 Diabetes Mellitus (T2DM)

LAY MON KHIN, KAZUYA FUJIHARA, MARIKO HATTA, YASUNAGA TAKEDA, SAKIKO Y. MORIKAWA, CHIKA HORIKAWA, NORIKO KATO, MITSUTOSHI KATO, HIROSHI MAEGAWA, HIROHITO SONE

Diabetes 72 ( Supplement_1 ) 2023.6

Publishing type：Research paper (scientific journal) Publisher：American Diabetes Association

We analyzed the association between dietary Mn intake and obesity measured by BMI after adjustment for intake of nutrients and food groups in people with T2DM in Japan. Participants were 1567 people, 63% male, aged 30 to 89 y who were in the Japan Diabetes Clinical Data Management Study Group (JDDM), one of the largest cohorts of Japanese with diabetes. Intake of food groups was determined by a validated self-administered food frequency questionnaire based on food groups. Obesity was defined as BMI ≥25 kg/m2. Multivariate logistic regression analysis assessed the relationship between quartiles of dietary Mn intake and obesity stratified by age. Participants aged 30 to 89 y were grouped according to the following quartiles for age: 30-54 y, 55-63 y, 64-71 y, and 72-89 y. Compared to the lowest quartile (Q1) for Mn, a significant negative association between Mn and BMI was found in males for all quartiles of Mn (OR [95%CI] of Q2= 0.643 [0.424 - 0.973], Q3= 0.607 [0.374 - 0.986], Q4= 0.398 [0.218 - 0.728], p trend = 0.028) with adjustment for characteristics such as age, sex, current smoking, drinking, insulin, oral hypoglycemic agents treatment, activity, energy intake and macronutrients intake. However, statistical significance disappeared after adding total fiber as a covariate. Compared to the lowest quartile for Mn, the highest quartile of Mn was inversely associated with BMI in the younger age group (30-54 y [OR= 0.296 [0.088 - 0.996]]) even after total fiber adjustment. Multivariate analysis of food groups (rice, vegetables, soy products) that were highly correlated with Mn as covariates showed that the relationships between Mn intake and obesity were maintained (p trend for rice, vegetables, soy = &lt;0.001, 0.187, 0.010) in all participants. In summary, higher dietary Mn intake was independently associated with a lower BMI, especially in the younger group and males. Future prospective or intervention studies are expected to confirm this result.

Disclosure

L.Khin: None. H.Sone: Research Support; Novo Nordisk, Astellas Pharma Inc., Kyowa Kirin Co., Ltd., Taisho Pharmaceutical Holdings Co., Ltd., Ono Pharmaceutical Co., Ltd., Eisai Co., Ltd., Takeda Pharmaceutical Co., Ltd. Jddm study group: n/a. K.Fujihara: None. M.Hatta: None. Y.Takeda: None. S.Y.Morikawa: None. C.Horikawa: None. N.Kato: None. M.Kato: None. H.Maegawa: None.

DOI： 10.2337/db23-1713-p

researchmap

738-P: Lifestyle Intervention Program with Smartphone App Augmented by Intermittently Scanned Continuous Glucose Monitoring for People at High Risk of Diabetes—Randomized Controlled Trial

MASARU KITAZAWA, HIROSHI SUZUKI, CHIKA HORIKAWA, YASUNAGA TAKEDA, IZUMI IKEDA, MARIKO HATTA, MIDORI IWANAGA, TAKAHO YAMADA, KAZUYA FUJIHARA, HIROHITO SONE

Diabetes 72 ( Supplement_1 ) 2023.6

Publishing type：Research paper (scientific journal) Publisher：American Diabetes Association

We examined the effects of a lifestyle intervention program with a smartphone app augmented by intermittently scanned continuous glucose monitoring (isCGM) of persons at high risk of developing diabetes in a 12-week randomized open-label trial (UMIN00004640). The program monitored blood glucose fluctuations and lifestyle habits and displayed them in an easy-to-understand interface as well as provided personalized lifestyle intervention messages. The primary endpoint was the change in time in range (TIR) of 70-140 mg/dL between intervention (App) and control (C) groups. Among 168 patients (mean age 48.1 y, mean BMI 26.6 kg/m2, and male 80.4%), 82 and 86 were assigned to the App group and C group, respectively. After 12 weeks, TIR of 70-140 mg/dL significantly improved in the App group compared to the C group (-2.6 min/day vs. +31.5 min/day, p=0.03). Changes in time above range (&gt;140 mg/dL; -20.9 min/day vs. -22.6 min/day, p=0.86) did not differ, whereas time below range (&lt;70 mg/dL; +23.5 min/day vs. -8.9 min/day, p=0.02) improved in App compared to C. BMI (-0.26 vs. -0.59, p=0.017) and carbohydrate intake (-4.4 kcal/day vs. -22.7 kcal/day, p=0.049) also improved in App compared to C. Intervention with a smartphone app and isCGM increased glycemic control with a decrease in carbohydrate intake and weight loss.

<p></p> Disclosure

M.Kitazawa: None. H.Sone: Research Support; Novo Nordisk, Astellas Pharma Inc., Kyowa Kirin Co., Ltd., Taisho Pharmaceutical Holdings Co., Ltd., Ono Pharmaceutical Co., Ltd., Eisai Co., Ltd., Takeda Pharmaceutical Co., Ltd. H.Suzuki: None. C.Horikawa: None. Y.Takeda: None. I.Ikeda: None. M.Hatta: None. M.Iwanaga: None. T.Yamada: None. K.Fujihara: None.

DOI： 10.2337/db23-738-p

researchmap

Recent updates in factors associated with incidence and screening of diabetic eye disease

Hirohito Sone

Journal of Diabetes Investigation 2023.6

中学生におけるスクリーンタイムがボディイメージの歪みと精神的健康度へ及ぼす影響

池田和泉, 藤原和哉, 森川咲子, 武田安永, 石黒創, 堀川千嘉, 山田貴穂, 小川洋平, 曽根博仁

日本内分泌学会雑誌 99 ( 1 ) 333 - 333 2023.5

The Reply

Ryoko Kawakami, Kiminori Kato, Hirohito Sone

The American Journal of Medicine 136 ( 5 ) e104 - e104 2023.5

ヘパプラスチンテストを取り入れた出血原因鑑別の検査戦略後天性第V因子欠乏症における経験

松田将門, 山田隆, 古山悠里, 柴崎康彦, 関義信, 星山良樹, 寺井崇二, 瀧澤淳, 曽根博仁, 増子正義

日本血栓止血学会誌 34 ( 2 ) 262 - 262 2023.5

Incidence and predictors of remission and relapse of type 2 diabetes mellitus in Japan: Analysis of a nationwide patient registry Reviewed International journal

Hirohito Sone

Diabetes, Obesity and Metabolism 25 ( 8 ) 2227 - 2235 2023.5

Language：English Publishing type：Research paper (scientific journal)

AIMS: To determine the incidence of remission and 1-year relapse from remission and associated factors in patients with type 2 diabetes. MATERIALS AND METHODS: A total of 48 320 Japanese patients with type 2 diabetes aged ≥18 years, with glycated haemoglobin (HbA1c) levels ≥48 mmol/mol (6.5%) and/or glucose-lowering drug prescription, were identified from databases of specialist clinics from 1989 and followed until September 2022. Remission was defined as HbA1c <48 mmol/mol at least 3 months after cessation of a glucose-lowering drug. Relapse was defined as failure to maintain remission for 1 year. Factors associated with remission and relapse were evaluated by logistic regression analysis. RESULTS: The overall incidence of remissions per 1000 person-years was 10.5, and for those with HbA1c levels of 48 to 53 mmol/mol (6.5% to 6.9%), those taking no glucose-lowering drugs at baseline, and those with a ≥10% body mass index (BMI) reduction in 1 year, it was 27.8, 21.7 and 48.2, respectively. Shorter duration, lower baseline HbA1c, higher baseline BMI, higher BMI reduction at 1 year, and no glucose-lowering drugs at baseline were significantly associated with remission. Among 3677 persons with remission, approximately two-thirds (2490) relapsed within 1 year. Longer duration, lower BMI at baseline, and lower BMI reduction at 1 year were significantly associated with relapse. CONCLUSIONS: The results showed that the incidence of remission and predictors of relapse, especially baseline BMI, might differ greatly between East Asian and Western populations. Furthermore, the relationships of BMI reduction with remission and relapse may be greater in East Asian than in Western populations, implying ethnic differences in returning from overt hyperglycaemia to nearly normal glucose levels.

DOI： 10.1111/DOM.15100

Web of Science

PubMed

researchmap

Reduced incidence of cardiovascular disease in patients with type 2 diabetes through the integrated improvement of diabetes care by comparing two prospective observational cohorts in real-world clinical practice (JDDM 72) International journal

Hirohito Sone

Diabetes Research and Clinical Practice 202 110674 - 110674 2023.4

Language：English Publishing type：Research paper (scientific journal)

AIM: To investigate whether any reduction in all-cause mortality and cardiovascular disease morbidity was found over the decade in type 2 diabetes on real-world practice. METHODS: A prospective observational study was performed by following two independent cohorts recruited in 2004 (n = 3286, Cohort 1) and 2014 (n = 3919, Cohort 2). The primary outcome was a composite of onset of cardiovascular disease and death. Cox proportional hazards analysis was used to explore any difference between Cohort 2 and Cohort 1 for the composite endpoints and cardiovascular disease after adjustment for covariates and accumulation of five risks (smoking, HbA1c, blood pressure, lipids, and albuminuria) outside target ranges. RESULTS: During the 8-year follow-up, 391 (11.9%) and 270 (6.9%) primary outcomes, and 270 (8.2%) and 161 (4.1%) cardiovascular diseases occurred in Cohort 1 and Cohort 2, respectively. Cohort 2 (vs. Cohort 1) exhibited a significant risk reduction for composite endpoints (HR 0.73, 95% CI 0.62 to 0.86) and cardiovascular disease (HR 0.64, 95% CI 0.52 to 0.79), and similarly exhibited a significant reduction independent of the accumulation of the five risks. CONCLUSIONS: The significant reduction of Cohort 2 for cardiovascular disease independent of the baseline covariates suggests an integrated effect delivered by the recent treatment advances.

DOI： 10.1016/J.DIABRES.2023.110674

Web of Science

PubMed

researchmap

耐糖能や年齢で層別化した血清アミラーゼ低値およびその経時的減少が2型糖尿病発症に及ぼす影響の縦断的検討

池田和泉, 藤原和哉, 大澤妙子, 武田安永, 治田麻里子, 松林泰弘, 児玉暁, 森保道, 本田律子, 門脇孝, 荒瀬康司, 曽根博仁

糖尿病 66 ( Suppl.1 ) S - 215 2023.4

糖尿病(DM)に5つの生活習慣関連因子(Cardiovascular Health Metrics)不良を伴うと腎透析導入(HD)リスクは著明に上昇する

大澤妙子, 藤原和哉, 山田万祐子, 矢口雄大, 佐藤隆明, 北澤勝, 松林泰弘, 山田貴穂, 曽根博仁

糖尿病 66 ( Suppl.1 ) S - 197 2023.4

新規に開発された体力指標フィジカルスコアによるメタボリックシンドローム発症予測能の検討

佐藤隆明, 藤原和哉, 山田万由子, 張かおり, 矢口雄大, 山本正彦, 北澤勝, 石黒創, 大澤妙子, 山田貴穂, 加藤公則, 曽根博仁

糖尿病 66 ( Suppl.1 ) S - 309 2023.4

JDDM登録患者4万8千人の2型糖尿病患者における新たに定義された世界共通定義による寛解(remission)の発生頻度と関連因子

藤原和哉, 松林泰弘, 佐藤隆明, 山田万祐子, 矢口雄大, 大澤妙子, 岩永みどり, 山崎勝也, 前川聡, 山田貴穂, 曽根博仁

糖尿病 66 ( Suppl.1 ) S - 194 2023.4

日本人ビッグデータにより血糖を含む全構成項目閾値を心血管疾患予測に最適化した新メタボリックシンドローム基準の有用性評価

三ツ間友里恵, 藤原和哉, 山田万祐子, 村井幸四郎, 佐藤隆明, 矢口雄大, 山本正彦, 大澤妙子, 北澤勝, 松林泰弘, 岩永みどり, 山田貴穂, 曽根博仁

糖尿病 66 ( Suppl.1 ) S - 172 2023.4

糖尿病/高血圧/肥満と脂肪肝との関連が心不全発症に与える影響についての検討

松林泰弘, 藤原和哉, 山田万祐子, 佐藤隆明, 矢口雄大, 山本正彦, 石黒創, 大澤妙子, 北澤勝, 岩永みどり, 山田貴穂, 曽根博仁

糖尿病 66 ( Suppl.1 ) S - 174 2023.4

Network meta-analysis of glucose-lowering drug treatment regimens with the potential risk of hypoglycemia in patients with type 2 diabetes mellitus in terms of glycemic control and severe hypoglycemia Reviewed

Hirohito Sone

Journal of Investigative Medicine 2023.4

写真撮影とAIを活用した食事記録スマートフォンアプリによる日常の食事記録の妥当性検証

北澤勝, 堀川千嘉, 長谷川美代, 武田安永, 治田麻理子, 松林泰弘, 山田貴穂, 児玉暁, 藤原和哉, 曽根博仁

糖尿病 66 ( Suppl.1 ) S - 230 2023.4

コンドロイチン硫酸と糖尿病性神経障害の関連の検討

石黒創, 牛木隆志, 五十嵐道弘, 曽根博仁

新潟県医師会報 ( 877 ) 12 - 14 2023.4

Utility of a Physical Fitness Score in Screening for Chronic Diseases International journal

Hirohito Sone

Journal of Sports Science and Medicine 22 ( 1 ) 98 - 110 2023.3

Language：English Publishing type：Research paper (scientific journal)

We developed a new Physical Score (PS) consisting of comprehensive physical fitness indicators and elucidated the association between the resultant PS and metabolic diseases, i.e., diabetes, hypertension, dyslipidemia, fatty liver, and metabolic syndrome (MetS), among Japanese. Analyzed were 49,850 persons (30,039 men) aged 30 to 69 y who underwent physical fitness tests. Principal component analysis was performed on the correlation matrix of the physical fitness test results (relative grip strength, single-leg balance with eyes closed, and forward bending) according to sex and age. We defined the PS as the first principal component score. A formula was developed for various age groups comprised of men and women from 30 to 69 years of age from which the PS for each age and sex was calculated. The PS for both men and women was normally distributed with a value of 0 ± 1.15-1.16. Multivariate logistic regression analysis showed that the risk of metabolic diseases increased approximately 1.1-1.6 times per each 1-point reduction in the PS. The association between PS and MetS was particularly strong in that a 1-point reduction in the PS increased the risk of MetS by 1.54 times (95% confidence interval 1.46 to 1.62) in men and by 1.21 times (1.15 to 1.28) in women. The association between a lower PS and disease risk was stronger in younger men for fatty liver and in older men for MetS. Conversely, in women, the association between a lower PS and disease risk was stronger in older women for fatty liver and in younger women for MetS. For diabetes, hypertension, and dyslipidemia, the change in the impact of PS reductions across age groups was small. The PS is a useful and simple non-invasive tool for screening Japanese people for metabolic diseases.

DOI： 10.52082/JSSM.2023.98

Web of Science

PubMed

researchmap

　 PREV - NEXT 　

<SONE, Hirohito>

Papers - SONE, Hirohito